On the 2025 SNO Annual Assembly, investigators introduced interim outcomes from the first-in-human part 1 LCCC 2059 examine exhibiting that intraventricular infusion of B7-H3–directed CAR T-cell remedy was properly tolerated in sufferers with recurrent glioblastoma at doses as much as 1 x 10⁷ CAR T cells per infusion, assembly the first security goal.
Amongst 9 evaluable sufferers who have been enrolled throughout three dose ranges (2 x 106, 3 sufferers; 5 x 106, 3 sufferers; 1 x 107, 3 sufferers) of CAR T-cells per infusion, no dose-limiting toxicities (DLTs) have been reported. A complete of two sufferers developed delicate cytokine launch syndrome (CRS); no sufferers skilled reasonable or extreme CRS. No sufferers had immune effector cell–related neurotoxicity syndrome of any grade, and no grade 3 (extreme) or greater adversarial results have been deemed associated to CAR T-cell infusion. Notably, two sufferers had reasonable headache. No sufferers wanted to be admitted to the intensive care unit or obtain toxicity administration therapy with Kineret (anakinra) or Actemra (tocilizumab).
Among the many 9 evaluable sufferers, the median age was 49 years, and 78% of sufferers have been male. All sufferers accomplished the scheduled three weekly infusions. Finest radiographic responses included partial response (PR; 22%; 2 sufferers) and secure illness (22%; 2 sufferers), translating to a illness management fee of 44%. One of many sufferers with PR achieved this response by 24 weeks and remained in response for eight months after infusion. The opposite affected person with PR achieved this response by the top of the DLT interval. The median general survival was 10.2 months.
“That is an ongoing scientific trial, and we’re enrolling on dose stage 5, [which is 6 x 107 CAR T cells], presently,” lead examine creator Dr. Yasmeen Rauf, said within the presentation.
Rauf is an assistant professor of neurology and neurosurgery on the College of North Caroline (UNC) College of Medication, in addition to the interim division chief of Neuro-Oncology on the UNC Lineberger Complete Most cancers Middle in Chapel Hill.
What’s at present identified in regards to the story of B7-H3 focused remedy in mind most cancers?
Presently sufferers with glioblastoma have a median survival of roughly 14.6 months and 5-year survival charges under 5%. B7-H3 is extensively expressed in glioblastoma and has minimal expression in regular mind tissue, making it a beautiful therapeutic goal.
B7-H3–directed CAR T-cell remedy is below investigation in different mind most cancers populations as properly. As an illustration, in Could 2025, the FDA granted regenerative medication superior remedy designation to the CAR T-cell remedy BCB-276, which targets B7-H3, for the therapy of sufferers with diffuse intrinsic pontine glioma.
What was the design of the part 1 trial investigating B7-H3–directed CAR T-cell remedy in sufferers with glioblastoma?
This dose-escalation examine used a 3 plus 3 design. It enrolled sufferers a minimum of 18 years of age with histologically confirmed recurrent glioblastoma, a Karnofsky efficiency rating of better than 60, and measurable illness of a minimum of 1 centimeter. Sufferers weren’t permitted to have prior Avastin (bevacizumab) therapy.
Sufferers obtained three weekly intraventricular infusions throughout six deliberate dose ranges starting from 1 x 106 CAR T cells to 1 x 108 CAR T cells, adopted by a two-week DLT interval. Autologous CAR T cells have been manufactured by way of RNA electroporation. Radiographic responses have been measured each eight weeks per Immunotherapy Response Evaluation in Neuro-Oncology standards. Notably, sufferers who progressed on this examine therapy obtained extra therapy.
“It takes us about three to 4 weeks, typically 5 weeks, for manufacturing of the CAR T cells,” Rauf famous.
Security and tolerability served as the first finish level of the trial. Secondary finish factors have been feasibility and preliminary efficacy.
What did a case examine present in regards to the efficacy of B7-H3–directed CAR T-cell remedy in a particular affected person?
Rauf introduced findings from a case of a 46-year-old affected person with IDH wild-type glioblastoma who obtained six weeks of concurrent radiation and Temodar (temozolomide), adopted by 5 cycles of adjuvant temozolomide. After presenting with development, this affected person obtained two cycles of Gleostine (lomustine). Upon second development, the affected person was enrolled onto LCCC 2059 and obtained three weekly infusions of CAR T cells at dose stage 3 x 107 CAR T cells. Following the DLT interval, this affected person’s mind MRI appeared secure, and a subsequent MRI displayed a sturdy PR.
References
- “Security and tolerability of intraventricular infusion of B7-H3.CAR-T cells in recurrent glioblastoma,” by Dr. Rauf Y, Higgins D, Buchannan B, et al. Offered at: 2025 SNO Annual Assembly; November 19-23, 2025; Honolulu, Hawaii. Summary CTIM-32.
- “FDA grants regenerative medication superior remedy designation for BrainChild Bio’s B7-H3 CAR T-cell remedy for incurable pediatric mind tumors.” Information launch. BrainChild Bio. Could 15, 2025. Accessed Could 19, 2025. https://brainchildbio.com/wp-content/uploads/2025/05/BrainChild-Bio-RMAT-PR_FINAL.pdf
For extra information on most cancers updates, analysis and schooling,
